OBJECTIVES: The purpose of this study was to explore the incremental cost-effectiveness ratio (ICER) ranges of variant health interventions. METHODS: We performed the systematic review of cost-effectiveness studies about health interventions. Comprehensive literature review was conducted using MEDLINE and EMBASE with a publication date before March 24, 2009.  We selected literatures based on the following criteria; 1) written in the English and Korean languages; 2) contained information on interventions relevant to diseases or health problems; 3) reported cost per year of life saved or contained sufficient information to calculate this ratio; 4) study methodology related to economic evaluations such as cost-utility analysis (CUA) and cost-effectiveness analysis (CEA), and 5) contained information whether the health intervention is cost-effective or not. We calculated the mean of reported ICER of major therapeutic area and major countries from all selected literature and extracted implicit ICER threshold based on the author’s conclusion about cost-effectiveness. The value of ICER in each literature was converted to 2008 value reflecting exchange rate and price index. RESULTS: A total of 3662 articles were originally identified from the planned searching strategy. 1466 among them were finally included to calculate ICER range after abstract review and/or full text review.  Two independent reviewers worked to select relevant articles and extract data.  Mean incremental cost per Quality-adjusted-life-years-gained or Life-years-gained were US$130,514,  US$25,446, US$30,448, US$70,420 for cancer, cardiovascular diseases, endocrine disease, and musculoskeletal disease, respectively. The ICER according to countries were also varied a lot. If we see the author’s judgment on cost-effectiveness, some interventions were recommended as cost-effective even in the case ICER were approximately US$80,000, US$75,000, US$200,000 for UK, Canada, and USA. CONCLUSIONS: The judgment on cost-effective interventions could be different according to countries and disease. It tends to have higher ICER in severe disease and in developed countries.